Cubist Systematic Strategies, LLC Applied Therapeutics Inc. Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.25 - $7.4 $235,068 - $773,115	104,475 Added 178.29%	163,072 $1.11 Million
Q4 2023 Feb 14, 2024	BUY	$1.84 - $3.35 $99,516 - $181,184	54,085 Added 1198.69%	58,597 $196,000
Q3 2023 Nov 14, 2023	BUY	$1.26 - $2.77 $5,685 - $12,498	4,512 New	4,512 $11,000
Q1 2022 May 16, 2022	SELL	$1.48 - $6.22 $5,014 - $21,073	-3,388 Reduced 45.62%	4,038 $9,000
Q4 2021 Feb 14, 2022	BUY	$8.77 - $18.29 $29,879 - $62,314	3,407 Added 84.77%	7,426 $66,000
Q3 2021 Nov 15, 2021	BUY	$13.54 - $22.06 $54,417 - $88,659	4,019 New	4,019 $67,000
Q2 2021 Aug 16, 2021	SELL	$14.05 - $25.04 $35,265 - $62,850	-2,510 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$16.57 - $28.65 $120,115 - $207,683	-7,249 Reduced 74.28%	2,510 $47,000
Q4 2020 Feb 16, 2021	SELL	$15.44 - $24.23 $58,394 - $91,637	-3,782 Reduced 27.93%	9,759 $215,000
Q3 2020 Nov 16, 2020	BUY	$19.43 - $35.36 $245,556 - $446,879	12,638 Added 1399.56%	13,541 $281,000
Q2 2020 Aug 14, 2020	BUY	$29.41 - $51.23 $26,557 - $46,260	903 New	903 $33,000

140

112M

1.68M

1.91M

Ticker APLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,700
Market Cap $42.3M
Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.